DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

Phase 1

Recruiting

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia

Interventions: Drug: Digoxin
Drug: Midazolam
Drug: Etavopivat
Drug: Pitavastatin
Drug: Rosuvastatin
Drug: Metformin

First Posted Date: 2025-02-07

Last Posted Date: 2025-03-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29

Registration Number: NCT06813924

Locations: 🇺🇸
ICON-Salt Lake City, Salt Lake City, Utah, United States

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump

Phase 1

Recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: NNC0471-0119 H
Drug: Insulin aspart

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 43

Registration Number: NCT06809621

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

Not yet recruiting

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Insulin Icodec

First Posted Date: 2025-02-04

Last Posted Date: 2025-02-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 630

Registration Number: NCT06807190

A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program

Conditions: Overweight, Obesity

First Posted Date: 2025-02-03

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 200

Registration Number: NCT06805539

Locations: 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
🇩🇰
Aarhus Universitetshospital, Steno Diabetes Center Aarhus, Aarhus, Denmark

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Phase 2

Recruiting

Conditions: Diabetes Mellitus, Type 2
Diabetic Peripheral Neuropathy

Interventions: Drug: CagriSema (Cagrilintide B and Semaglutide I)
Drug: Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)

First Posted Date: 2025-01-29

Last Posted Date: 2025-04-22

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 134

Registration Number: NCT06797869

Locations: 🇩🇰
Steno Diabetes Center Odense, Odense C, Denmark
🇬🇧
Kings College Hospital, London, United Kingdom
🇺🇸
eStudySite, La Mesa, California, United States

and more 44 locations

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Phase 3

Recruiting

Conditions: Obesity

Interventions: Drug: Placebo cagrilintide
Drug: Cagrilintide
Drug: Placebo semaglutide
Drug: Semaglutide

First Posted Date: 2025-01-17

Last Posted Date: 2025-05-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 400

Registration Number: NCT06780449

Locations: 🇺🇸
Valley Clinical Trials, Covina, California, United States
🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States

and more 33 locations

A Real-world Assessment in Implementation of the MASH Patient Care Pathway in Chinese Population Using the Meinian Health Check-up Database

Completed

Conditions: Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) & Steatohepatitis (MASH)

First Posted Date: 2024-12-18

Last Posted Date: 2025-01-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1233970

Registration Number: NCT06741111

Locations: 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India

A First-in-human Research Study on How NNC0662-0419 Works in People Living With Overweight or Obesity

Phase 1

Recruiting

Conditions: Overweight
Obesity

Interventions: Drug: NNC0662-0419
Other: Placebo (NNC0662-0419)

First Posted Date: 2024-12-17

Last Posted Date: 2025-05-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 100

Registration Number: NCT06737536

Locations: 🇺🇸
Celerion, Lincoln, Lincoln, Nebraska, United States

A Study on How NNC0174-1213 Works in People With Overweight or Obesity.

Phase 1

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: NNC0174-1213 A
Drug: Cagrilintide B
Drug: Placebo A (NNC0174 1213 A)

First Posted Date: 2024-12-05

Last Posted Date: 2024-12-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 177

Registration Number: NCT06719011

Locations: 🇺🇸
ICON Early Phase Services, LLC, Salt Lake City, Utah, United States

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Phase 2

Recruiting

Conditions: Chronic Kidney Disease

Interventions: Drug: Placebo
Drug: NNC0519-0130
Drug: Semaglutide

First Posted Date: 2024-12-05

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 465

Registration Number: NCT06717698

Locations: 🇯🇵
Kato Clinic of Internal Medicine, Tokyo, Japan
🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
National Health Insurance Corporation Ilsan Hospital, Goyang, Korea, Republic of

and more 114 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy